KMT2E

Across TCGA pan-cancer cohorts, KMT2E mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KMT2E data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KMT2E mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated KMT2E expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where KMT2E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.925	.003	30	view →
HNSC	OS	Median	II,III,IV	0.794	0.983	.005	18	view →
CCRCC	OS	Median	All	0.958	0.687	.009	13	view →
LSCC	DFS	Tertile	III,IV	0.984	0.525	.012	12	view →
PDAC	OS	Median	All	0.922	0.798	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KMT2E–LUAD (OS)

Open the LUAD breakdown →